Centre Hospitalier Universitaire de Poitiers

Genetic Screening for Expanded FMR1 Alleles in a Moroccan Cohort With Unexplained Intellectual Disability

ABSTRACT Background Intellectual disability (ID) constitutes a major neurodevelopmental disorder (NDD), arising from diverse genetic and environmental aetiologies. Fragile X syndrome (FXS), caused by CGG repeat expansion in the FMR1 gene, is one of the most common inherited cause...

Initial treatment strategies and outcomes across haemodynamic thresholds and risk stratification in incident systemic sclerosis–associated pulmonary arterial hypertension: a EUSTAR analysis

OBJECTIVE: Real-world initial treatment strategies in SSc-PAH remain incompletely described. We aimed to characterise these strategies across haemodynamic thresholds and risk strata and evaluate outcome associations. METHODS: We analysed treatment-naïve SSc-PAH patients in EUSTAR...

Intermittent or Continuous Renal-Replacement Therapy in Acute Kidney Injury

BackgroundThe preferred method of renal-replacement therapy for acute kidney injury in critically ill patients remains uncertain. MethodsIn this multicenter, open-label, noninferiority trial, we randomly assigned critically ill adults with acute kidney injury who had indications...

Association between the site of emergency care and patient-centered outcomes in patients with cancer: rationale and design of the French COVER cohort

Patients living with cancer now account for a substantial and growing share of emergency department (ED) visits and carry a high burden of hospitalization and in-hospital death. Their acute presentations are frequently multifactorial - driven by disease progression, treatment tox...

Guidelines for Decisions to Withhold or Withdraw Life-Sustaining Treatments (LST) in Adult ICU

OBJECTIVE: The French Society of Anaesthesia and Intensive Care Medicine (Société française d'anesthésie et de réanimation, SFAR) and the French Society of Physical Medicine and Rehabilitation (Société Française de Médecine Physique et de Réadaptation (SOFMER)) aimed at providing...

Subcutaneous isatuximab by on-body-injector plus bortezomib, lenalidomide, and dexamethasone in newly diagnosed transplant-ineligible multiple myeloma: ISASOCUT study

Isatuximab–bortezomib–lenalidomide–dexamethasone (Isa-VRd) has emerged as a standard of care for newly diagnosed multiple myeloma transplant-ineligible patients. A subcutaneous (SC) formulation of isatuximab delivered via an on-body injector (OBI) has been developed to facilitate...

Relapsed/refractory WAldenström macroglobulinemia patients treated by VEnetoclax with or without anti-CD20 antibody: WAVE a retrospective study of the French CLL/WM group (FILO)

Abstract Recently venetoclax (Ven) monotherapy showed promising efficacy for relapsed/refractory (R/R) Waldenström macroglobulinemia (WM), a population with significant medical unmet need. We report the efficacy and safety of Ven associated or not with anti-CD20 therapy, in a rea...

End-of-induction circulating tumor DNA outperforms conventional cellular MRD for predicting early progression in follicular lymphoma: an ancillary study of the RELEVANCE randomized trial

In this ancillary study of the RELEVANCE phase III trial (NCT01650701), we performed the first direct intra-patient comparison of circulating tumor DNA (ctDNA)-based versus cellular t( BCL2 / JH ) translocation-based MRD at end of induction (EOI) in 278 patients with advanced FL,...

Serum GFAP and Age Accurately Distinguish AQP4 ‐ IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack

BACKGROUND: Serum neurofilament-light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are associated with multiple sclerosis (MS) activity. This study aimed to identify patient- and disease-level determinants of sNfL and sGFAP and to evaluate their ability to support dif...

Ociperlimab and tislelizumab in advanced esophageal squamous cell carcinoma (AdvanTIG-203): a phase II study

Patients with esophageal squamous cell carcinoma (ESCC) have an unmet need for new therapies that improve survival. In this phase II trial, patients received ociperlimab and tislelizumab (A) or placebo and tislelizumab (B) (NCT04732494). The primary endpoint was objective respons...

Improving diabetes management in older adults with cancer: a quality improvement project to enhance monitoring during steroid-based systemic anti-cancer therapy

PURPOSE: Older adults undergoing systemic anti-cancer therapy (SACT) with steroids are at high risk of developing steroid-induced hyperglycaemia (SIH). However, monitoring and management remain inconsistent. This quality improvement project (QIP) involved developing and evaluatin...

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

Abstract In previous analyses of MAIA, daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved progression-free survival and overall survival (OS) versus lenalidomide/dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM). We report...